Turnover: 23.7 billion EUR (2022)
Country: Denmark
- Novo Nordisk is a Danish pharmaceutical company specializing in diabetes and hormone treatments.
- Novo Nordisk has several different insulin brands, including NovoLog, Tresiba and Novolin R.
- Supplies around 50% of the world's insulin
News
Obesity, the golden goose for Novo Nordisk 21/06/2023
- Launch of Wegovy appetite suppressant in 2021.
- Novo Nordisk invests €5 billion in new production lines this year.
- Wegovy launched in Denmark and Norway last month.
- Potential sales of Wegovy for 2021 estimated at $4.2 billion.
- Novo Nordisk market capitalization exceeds $300 billion.
- Novo Nordisk sales growth forecast for 2023 revised to between 24% and 30% for this year.
- Potential sales of anti-diabetic Ozempic to reach $11.1 billion in 2023.
- Market for anti-obesity drugs estimated at over $100 billion in annual sales.
- 813 million people worldwide suffer from obesity, a figure that could rise to 1.5 billion by 2035.
Connected devices: Novo Nordisk wants to buy Auvergne medtech Biocorp 05/06/2023
- Partnership in 2021 between Novo Nordisk and Biocorp
- Biocorp based in Issoire, south of Clermont-Ferrand (Puy-de-Dôme)
- Biocorp partnerships with Sanofi, Becton Dickinson (BD), Merck and Novo Nordisk
- Acquisition of Biocorp valued at over 150 million euros
- Biocorp, founded in 2004, employs 80 people, and will achieve sales of 11.7 million euros in 2022.
Diabetes: Novo Nordisk invests 130 million euros in its major French plant 21/01/2023
- The Danish group is Europe's leading market capitalization in the pharmaceuticals sector
- The group supplies 50% of the world's insulin, with sales of €18.9 billion
- France is world production center for insulin cartridges and vials
- 130 million investment in insulin cartridge and vial production to triple Flextouch pen production capacity
- Novo Nordisk's second-largest site after Denmark, and the largest private employer in the Eure-et-Loir département (1,450 employees)